Inactief instrument

Andere talen Ventrus Biosciences Inc Nasdaq

Aandelen

US9228221019

slotkoers Nasdaq Andere beurzen
- ^USD	-

05/06	Assembly Biosciences presenteert nieuwe gegevens over de hepatitis D virus introductieremmer Abi-6250 op het Easl Congress 2024	CI
08/05	Assembly Biosciences, Inc. rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024	05/06
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024	05/06
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024	22/05
Assembly Biosciences: Q1 Earnings Snapshot	09/05
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights	08/05
Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights	28/03
Assembly Biosciences Announces Effective Date of Reverse Stock Split	08/02
Assembly Biosciences Announces Effective Date of Reverse Stock Split	08/02
Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	19/01
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	04/01
Assembly Biosciences Provides Anticipated Development Milestones for 2024	04/01
Assembly Biosciences Provides Anticipated Development Milestones for 2024	04/01
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board	07/12
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	10/11
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	10/11
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®	10/11
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®	10/11
Assembly Biosciences: Q3 Earnings Snapshot	08/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ventrus Biosciences Inc Nasdaq

Aandelen

US9228221019

Andere talen

Filters